Humana | HUM | Long at $220.00
Atualizado
Humana 
HUM took a nosedive to "crash" levels (based on my selected simple moving averages (SMA)) this morning after a lower-performance rating for a widely used Medicare insurance plan is expected to hurt enrollments for 2025 (and will potentially hit the health insurer's revenue and bonus payments in 2026). However, I view this massive drop as an opportunity for an initial long entry for a great value stock. The company is strong, highly rated among patients, and solid fundamentals despite the anticipated earnings drop. From a technical analysis perspective, it touched my "crash" SMA, but may dip further after a dead cat bounce to the 190s in the coming days or weeks. But, predicting true bottom is a fool's game, so at $220.00, HUM is in a personal buy zone for an initial long entry.
Target #1 = $250.00
Target #2 = $275.00
Target #3 = $314.00
Target #4 = $340.00
HUM took a nosedive to "crash" levels (based on my selected simple moving averages (SMA)) this morning after a lower-performance rating for a widely used Medicare insurance plan is expected to hurt enrollments for 2025 (and will potentially hit the health insurer's revenue and bonus payments in 2026). However, I view this massive drop as an opportunity for an initial long entry for a great value stock. The company is strong, highly rated among patients, and solid fundamentals despite the anticipated earnings drop. From a technical analysis perspective, it touched my "crash" SMA, but may dip further after a dead cat bounce to the 190s in the coming days or weeks. But, predicting true bottom is a fool's game, so at $220.00, HUM is in a personal buy zone for an initial long entry.Target #1 = $250.00
Target #2 = $275.00
Target #3 = $314.00
Target #4 = $340.00
Nota
Target #1 reached for a 13.6% gain.Trade ativo
Target #2 reached for a 25% gain.
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.